- Home
- APPS vs INBX Comparison
APPS vs INBX Comparison
Compare APPS & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APPS | INBX |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.5M | 430.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | APPS | INBX |
|---|---|---|
| Price | $5.00 | $79.23 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $6.25 | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 253.2K |
| Earning Date | 02-04-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $525,092,000.00 | $1,400,000.00 |
| Revenue This Year | $13.99 | $563.00 |
| Revenue Next Year | $11.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.82 | N/A |
| 52 Week Low | $1.65 | $10.81 |
| 52 Week High | $8.28 | $94.57 |
Technical Indicators
Market Signals| Indicator | APPS | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 45.79 | 48.39 |
| Support Level | $5.00 | $76.22 |
| Resistance Level | $5.27 | $81.79 |
| Average True Range (ATR) | 0.26 | 6.13 |
| MACD | 0.02 | -1.33 |
| Stochastic Oscillator | 33.49 | 21.88 |
Price Performance
Historical ComparisonAbout APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.